The Cooper Companies ended its nine-month strategic review of the CooperSurgical unit on September 9, 2026, deciding to keep the business after bids failed to meet shareholder interests. The company had launched the review in December 2025, and management said the offers undervalued the business because of temporary factors including a new competitor in the non-hormonal IUD space and recent fertility litigation expenses. To signal conviction, the board authorized a new $1 billion share repurchase program, while Bank of America noted that a nine-month auction ending with no deal shows buyers would not meet management's valuation. The third-quarter miss and a cut outlook sent the stock down about 15% to a 52-week low near $51, with shares at 18 times earnings and down roughly 40% from their high. CooperVision, the core contact lens business, posted flat organic revenue growth in the third quarter as the company began reducing U.S. channel inventory ahead of fiscal 2027, while third-quarter free cash flow hit a record $273 million and short interest stood at approximately 5.3% of the float.
The Cooper Companies, IncCooper ended the CooperSurgical sale review with no deal, reported a Q3 miss and cut its outlook, sending shares down about 15%
China Grand Pharmaceutical and Healthcare Holdings Ltd
Amgen Inc
Bank of America Corp